Tuesday, October 4, 2022


Biotechnology News Magazine

Parsortix System Results Published As a Poster at AACR 2022

Poster demonstrated use of Parsortix workflow for triple negative breast cancer

Latest Posts

BRAINBox Solutions Announces New U.S. Patent Allowance, Strengthening Biomarker Portfolio for Multi-Modal Mild Traumatic Brain Injury Test

BRAINBox Solutions notes the new patent covers both diagnosis of TBI and patient monitoring post-injury, particularly for determining return to work or play.

New Initiative Brings Leading Life Sciences Companies Together To Drive Collective Impact in Awareness, Diagnosis, Care, and Health Equity for Patients with Amyloidosis

Despite notable progress in recent years, amyloidosis patients continue to experience high unmet needs and gaps in treatment and support.

GBS Inc. Acquires Intelligent Fingerprinting Limited and its Proprietary Drugs of Abuse Screening Technology

Steven Boyages, CEO of GBS Inc. stated, “We believe this acquisition generates significant value for our shareholders, and I am extremely excited to be on the forefront of this transition. Bringing IFP under the GBS umbrella marks a significant advancement toward achieving our strategic goals of improving patients’ lives outside of saliva-based glucose testing and laying the pathway in becoming a leader in the development of rapid, non-invasive diagnostic solutions. We remain excited to accelerate our strategy and revenue growth through this collaboration with IFP.”

Araris Biotech Closes $24 Million Financing Round

Araris Biotech notes the proceeds from the financing will be used to support the further development and advancement of Araris’ antibody-drug conjugate (ADC) candidates, created using the Company’s proprietary linker technology, as Araris moves closer toward clinical development.

Parsortix System

ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, is pleased to announce that the Company has presented a poster showcasing the Parsortix®system at the American Association for Cancer Research Conference (AACR) 2022, held in New Orleans, United States on 8-13 April 2022.

The research presented related to the use of the Parsortix system with triple negative breast cancer (TNBC) patients. TNBC is a form of invasive breast cancer, which has limited treatment choices and a poor prognosis.

The poster attracted industry interest as it demonstrated the ability to analyse cancer cells harvested from patient blood samples, known as circulating tumour cells (CTCs), for key markers of interest and, as a result of its capability to investigate both mesenchymal and epithelial CTCs, a significantly higher positivity rate than alternative approaches. Key features included the high proportion of CTCs of mesenchymal phenotype and the high proportion of patient samples with CTC clusters, both of which are key differentiating factors of the Parsortix system.

ANGLE is offering this workflow as part of its pharma services business for longitudinal monitoring of patients in cancer drug trials.

The poster is available online at https://angleplc.com/library/publications/#posters.

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine